학술논문
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
Document Type
Article
Author
Galle, Peter R ; Finn, Richard S; Qin, Shukui; Ikeda, Masafumi; Zhu, Andrew X; Kim, Tae-You; Kudo, Masatoshi; Breder, Valeriy; Merle, Philippe; Kaseb, Ahmed; Li, Daneng; Mulla, Sohail; Verret, Wendy; Xu, Derek-Zhen; Hernandez, Sairy; Ding, Beiying; Liu, Juan; Huang, Chen; Lim, Ho Yeong; Cheng, Ann-Lii; Ducreux, Michel
Source
In The Lancet Oncology July 2021 22(7):991-1001
Subject
Language
ISSN
1470-2045